mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, Pradip K, Febbo, Phillip G, Bikoff, Rachel, Berger, Raanan, Xue, Qi, McMahon, Louis M, Manola, Judith, Brugarolas, James +5 more·2004·Nature Medicine

DOI 10.1038/nm1052

Cited by (962)

Items 301–400 of 962

Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model
Wenhao Guo, Yu Zhang, Ting Chen, Yongsheng Wang, Jianxin Xue, Yonggang Zhang, Wenjing Xiao, Xianming Mo, You Lü · 2010 · Journal of Cancer Research and Clinical Oncology
Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells
Ruslan Rafikov, Xutong Sun, Olga Rafikova, Mary Louise Meadows, Ankit A. Desai, Zain I. Khalpey, Jason X.‐J. Yuan, Jeffrey R. Fineman, Stephen M. Black · 2015 · Redox Biology
Interstitial 22q13 deletions not involving SHANK3 gene: A new contiguous gene syndrome
Vittoria Disciglio, Caterina Lo Rizzo, Maria Antonietta Mencarelli, Mafalda Mucciolo, Annabella Marozza, Chiara Di Marco, Antonio Massarelli, Valentina Canocchi, Margherita Baldassarri, Enea Ndoni et al. · 2014 · American Journal of Medical Genetics Part A
Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced Murine Lung Tumors
Courtney A. Granville, Noel A. Warfel, Junji Tsurutani, Mary Christine Hollander, Matthew Robertson, Stephen D. Fox, Timothy D. Veenstra, Haleem J. Issaq, R. Ilona Linnoila, Phillip A. Dennis · 2007 · Clinical Cancer Research
Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo
Hans‐Guido Wendel, Abba Malina, Zhen Zhao, Lars Zender, Scott C. Kogan, Carlos Cordon‐Cardo, Jerry Pelletier, Scott W. Lowe · 2006 · Cancer Research
Met acts on Mdm2 via mTOR to signal cell survival during development
Moumen, Anice, Patané, Salvatore, Porras, Almudena, Dono, Rosanna, Maina, Flavio · 2007 · Development
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Jean‐Yves Scoazec · 2012 · Neuroendocrinology
The Akt1-eNOS Axis Illustrates the Specificity of Kinase-Substrate Relationships in Vivo
Michael Schleicher, Jun Yu, Takahisa Murata, Berhad Derakhshan, Dmitriy N. Atochin, Li Qian, Satoshi Kashiwagi, Annarita Di Lorenzo, Kenneth D. Harrison, Paul Lee Huang et al. · 2009 · Science Signaling
MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1
Shaohua Xu, Guangbo Fu, Zhen Tao, Jun OuYang, Fanfei Kong, Bing‐Hua Jiang, Xiaoping Wan, Ke Chen · 2015 · Oncotarget
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
Sha Zhou, Lu Liu, H Li, Grant Eilers, Y Kuang, Si Shi, Z Yan, Xuchao Li, Joseph M. Corson, F Meng et al. · 2014 · British Journal of Cancer
The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
Ghada A. Soliman · 2013 · Nutrients
Evolving role of adiponectin in cancer-controversies and update
Arnav Katira, Arnav Katira, Peng Tan, Peng Tan · 2016 · Cancer Biology and Medicine
Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis
Zhi Hong Lu, Mark B. Shvartsman, Andrew Y. Lee, Jenny Meng Shao, Mollianne M. Murray, Raleigh D. Kladney, Dong Fan, Stan Krajewski, Gary Gene Chiang, Gordon Brent Mills et al. · 2010 · Cancer Research
A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size
Thomas Porstmann, Cláudio R. Santos, Caroline A. Lewis, Beatrice L. Griffiths, Almut Schulze · 2009 · Biochemical Society Transactions
Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-β
Rod A. Rahimi, Mahefatiana Andrianifahanana, Mark C. Wilkes, Maryanne Edens, Theodore J. Kottom, John Blenis, Edward B. Leof · 2008 · Cancer Research
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
Xiaoyong Fu, Charles Kent Osborne, Rachel Schiff · 2013 · The Breast
Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
Clay L. Efferson, Christopher T. Winkelmann, Christopher M. Ware, Timothy Sullivan, Saverio Giampaoli, Jennifer G. Tammam, Shailendra B. Patel, Giuseppe Mesiti, John F. Reilly, Raymond E. Gibson et al. · 2010 · Cancer Research
Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer
Cheng‐Yu Wu, Jiaoti Huang · 2006 · Journal of Biological Chemistry
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
Nicola J. Clegg, Suzana S. Couto, John Wongvipat, Haley Hieronymus, Brett Stewart Carver, Barry S. Taylor, Katharine Ellwood‐Yen, William L. Gerald, Chris Sander, Charles L. Sawyers · 2011 · PLoS ONE
Natural Product-Based Inhibitors of Hypoxia-Inducible Factor-1 (HIF-1)
Dale G. Nagle, Yudong Zhou · 2006 · Current Drug Targets
Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary
Seiji Mabuchi, Chiaki Kawase, Deborah A. Altomare, Ken‐ichirou Morishige, Masami Hayashi, Kenjiro Sawada, Kimihiko Ito, Yoshito Terai, Yukihiro Nishio, Andres J. Klein–Szanto et al. · 2010 · Molecular Cancer Therapeutics
Tyrosine kinase inhibitors
Carlos L. Arteaga, Jose M Baselga · 2004 · Cancer Cell
Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
John William Moroney, Siqing Fu, Stacy L. Moulder, Gerald Steven Falchook, Thorunn Helgason, Charles Levenback, David S. Hong, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock · 2012 · Clinical Cancer Research
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target
Lisa Salvatore, Maria Alessandra Calegari, Fotios Loupakis, Matteo Fassan, Brunella Di Stefano, Maria Bensi, Emilio Bria, Giampaolo Tortora · 2019 · Cancers
Sevoflurane promotes the expansion of glioma stem cells through activation of hypoxia-inducible factors in vitro
Q.Y. Shi, S.J. Zhang, L. Liu, Q.S. Chen, Lina Yu, F.J. Zhang, Min Yan · 2014 · British Journal of Anaesthesia
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, Hannah E., Cox, Lynne S. · 2018 · International Journal of Molecular Sciences
Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer
Henna Heinonen, Anni I. Nieminen, Matti Saarela, Anne H. Kallioniemi, Juha T. Klefström, Sampsa Hautaniemi, Outi M. Monni · 2008 · BMC Genomics
The Hypoxia-Inducible Factor and Tumor Progression Along the Angiogenic Pathway
M. Christiane Brahimi-Horn, Jacques Pouysségur · 2004 · International review of cytology
Oncological implications of hypoxia inducible factor-1α (HIF-1α) expression
Jill L. O’Donnell, Myles Joyce, Aoife M. Shannon, Judith H. Harmey, James Geraghty, David M. Bouchier‐Hayes · 2006 · Cancer Treatment Reviews
Predicting Relapse in Patients With Medulloblastoma by Integrating Evidence From Clinical and Genomic Features
Pablo Tamayo, Yoon‐Jae Cho, Aviad Tsherniak, Heidi E. Greulich, Lauren Ambrogio, Netteke Schouten-van Meeteren, Tianni Zhou, Allen B. Buxton, Marcel Kool, Matthew M. Meyerson et al. · 2011 · Journal of Clinical Oncology
Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
Chirayu Shah, Todd W. Miller, Shelby K. Wyatt, Eliot T. McKinley, Maria Graciela Olivares, Violeta M. Sanchez, Donald D. Nolting, Jason R. Buck, Ping Zhao, Mohammad Sib Ansari et al. · 2009 · Clinical Cancer Research
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura S Graham, Kalyan Banda, Alba Torres, Brett Stewart Carver, Yu Chen, Katie Pisano, Gregory Shelkey, Tracy Curley, Howard I. Scher, Tamara Levin Lotan et al. · 2018 · Investigational New Drugs
Inhibitory Effect of Rapamycin on Corneal Neovascularization In Vitro and In Vivo
Young-Sam Kwon, Hyun Sook Hong, Jae Chan Kim, Jun‐Seop Shin, Youngsook Son · 2005 · Investigative Ophthalmology & Visual Science
A therapeutic role for targeting c-Myc/Hif-1- dependent signaling pathways
Klaus Podar, Kenneth Carl Anderson · 2010 · Cell Cycle
Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells
Maleeha Rizvi, Noorulhuda Jawad, Yuantao Li, Marcela Paola Vizcaychipi, Mervyn Maze, Daqing Ma · 2010 · Experimental Biology and Medicine
Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma
Wei Liu, Helen C. Su, Isabel J. Hildebrandt, Michael E. Phelps, Johannes G. Czernin, Wolfgang Weber · 2008 · Clinical Cancer Research
MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E–Binding Protein 1–Mediated Inhibition of Autophagy
Bala S. Balakumaran, Alessandro Porrello, David S. Hsu, Wayne Glover, Adam Foye, Janet Y. Leung, Beth A. Sullivan, William C. Hahn, Massimo F. Loda, Phillip G. Febbo · 2009 · Cancer Research
Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway
M K Siu, Y-C Tsai, Y-S Chang, JuanJuan Yin, Florent Suau, W-Y Chen, Y-N Liu · 2014 · Oncogene
Rapamycin Inhibits Growth of Premalignant and Malignant Mammary Lesions in a Mouse Model of Ductal Carcinoma In situ
Ruria Namba, Lawrence J.T. Young, Craig K. Abbey, Lisa Kim, Patrizia Damonte, Alexander D. Borowsky, Jinyi Qi, Clifford G. Tepper, Carol L. MacLeod, Robert D. Cardiff et al. · 2006 · Clinical Cancer Research
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Mari Nakabayashi, Lilian Werner, Kevin Dale Courtney, Geoffrey Colin Buckle, William K. Oh, Glen J. Bubley, Julia H. Hayes, Douglas Jay Weckstein, Aymen A. Elfiky, Danny M. Sims et al. · 2012 · British Journal of Urology
A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
Courtney A. Granville, Regan Michelle Memmott, Andria Balogh, Jacopo Mariotti, Shigeru Kawabata, Wei Han, Jaclyn LoPiccolo, Jason Foley, David J. Liewehr, Seth M. Steinberg et al. · 2009 · PLoS ONE
RETRACTED ARTICLE: Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α
Sandra Cascio, Viviana Bartella, Alessandra Auriemma, Gregg J. Johannes, Antonio Dello Russo, Antonio Giordano, Eva Surmacz · 2007 · Oncogene · Retracted
The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
Eric Monsalves, Kyle Juraschka, Toru Tateno, Sameer Agnihotri, Sylvia L. Asa, Shereen Ezzat, Gelareh Mohammed Zadeh · 2014 · Endocrine Related Cancer
Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis
Faouzi Saliba, Sébastien Dharancy, Richard Lorho, Filoména Conti, Sylvie Radenne, Martine Neau‐Cransac, Monika Hurtova, Jean Hardwigsen, Yvon Calmus, Jérôme Dumortier · 2011 · Liver Transplantation
The evolving role of diet in prostate cancer risk and progression
Adeel Kaiser, Christopher P. Haskins, Mohummad Minhaj Siddiqui, Arif Hussain, Christopher R. D’Adamo · 2019 · Current Opinion in Oncology
Sirolimus-Based Immunosuppression Therapy in Liver Transplantation for Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria
Jian Zhou, Z. Wang, Zhixiong Wu, Shuang–Jian Qiu, Youcheng Yu, Xiaowu Huang, Zhao–You Tang, Jia Fan · 2008 · Transplantation Proceedings
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
de Aguirre, Patricia Boya, Dominique H. Bellet, Sandrine J. Faivre, Frédéric Troalen, Jean Bénard, Patrick Saulnier, Sally Hopkins-Donaldson, Uwe Zangemeister‐Wittke, Guido Kroemer et al. · 2004 · APOPTOSIS
Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten -Deficient Mouse Model of Prostate Cancer
Weisheng Zhang, Joe Jiang Zhu, Clay L. Efferson, Chris Ware, Jennifer G. Tammam, Minilik H. Angagaw, Jason Laskey, Kimberly A. Bettano, Shailaja Kasibhatla, John F. Reilly et al. · 2009 · Cancer Research
Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies
Benoît Bilanges, David Stokoe · 2007 · Oncogene
Status 5 Years after Bilateral Hand Transplantation
Stefan Schneeberger, Marina Ninković, Hildegunde Piza‐Katzer, M. Gabl, H. Hussl, Michael Rieger, W. Loescher, B. Zelger, Gerald Brandacher, Marina Ninković et al. · 2006 · American Journal of Transplantation
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
Caterina Nardella, Arkaitz Carracedo, Andrea Alimonti, Robin M. Hobbs, John G. Clohessy, Zhenbang Chen, Ainara Egia, Alessandro Fornari, Michelangelo Fiorentino, Massimo F. Loda et al. · 2009 · Science Signaling
Controlling cell growth and survival through regulated nutrient transporter expression
Aimee L. Edinger · 2007 · Biochemical Journal
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong, George Jabboure Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, S. Lindsay Davis, Ting Wang, Roula Albadine et al. · 2010 · Clinical Cancer Research
Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance
Josep Maria Campistol, Joan Albanell, Wolfgang Arns, I. Boletis, Jacques Dantal, Johan Willem de Fijter, Svend Mortensen, H.‐H. Neumayer, Ole M. Øyen, Julio Pascual et al. · 2007 · Nephrology Dialysis Transplantation
MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells
Michio Kosugi, Rehan Ahmad, Maroof Alam, Yasumitsu Uchida, Donald W. Kufe · 2011 · PLoS ONE
Mitochondria: The metabolic switch of cellular oncogenic transformation
Tan, Yan Qin, Zhang, Xi, Zhang, Shuwei, Zhu, Tao, Garg, Manoj, Lobie, Peter E., Pandey, Vijay · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
Quan Zhou, Zhansheng Deng, Yong Zhu, Haitao Long, Shaoxian Zhang, Jiali Zhao · 2009 · Medical Oncology
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
Gerhardt Attard, Debashis Sarker, Alison H. M. Reid, R. Molife, Chris C. Parker, Johann Sebastian De Bono · 2006 · British Journal of Cancer
A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors
Chad J. Creighton · 2007 · Oncogene
Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis
Susan Kasper · 2004 · Journal of Cellular Biochemistry
Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles
Elena J. Edelman, Alessandro Porrello, Justin Guinney, Bala S. Balakumaran, Andrea Bild, Phillip G. Febbo, Sayan Mukherjee · 2006 · Bioinformatics
Hypoxia-inducible factor 1 and its role in viral carcinogenesis
Sean Cuninghame, Robert Jackson, Ingeborg Zehbe · 2014 · Virology
Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.
Mojtaba Ghasemi, Iraj Nabipour, Abdolmajid Omrani, Zeinab Alipour, Majid Assadi · 2016 · PubMed Central
mTOR and cancer: reason for dancing at the crossroads?
GEORGE V. THOMAS · 2005 · Current Opinion in Genetics & Development
A genomic approach to identify molecular pathways associated with chemotherapy resistance
Richard F. Riedel, Alessandro Porrello, Emily Pontzer, Emily J. Chenette, David S. Hsu, Bala S. Balakumaran, Anil Potti, Joseph Roy Nevins, Phillip G. Febbo · 2008 · Molecular Cancer Therapeutics · Retracted
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
Xiaoyong Fu, Chad J. Creighton, Nrusingh C. Biswal, Vijetha Kumar, Martin J. Shea, Sabrina Herrera, Alejandro Contreras, Carolina Gutiérrez, Tao Wang, Sarmistha Nanda et al. · 2014 · Breast Cancer Research
Saururus cernuus lignans—Potent small molecule inhibitors of hypoxia-inducible factor-1
Chowdhury Faiz Hossain, Yong-Pil Kim, Scott R. Baerson, Lei Zhang, Richard K. Bruick, Kaleem A. Mohammed, Ameeta Kishore Agarwal, Dale G. Nagle, Yu-Dong Zhou · 2005 · Biochemical and Biophysical Research Communications
Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells
Mingyue Zhu, Junli Guo, Wei Li, Yan Lu, Shigan Fu, Xieju Xie, Hua Xia, Dong Xu, Yi Chen, Ming Quan et al. · 2015 · Oncotarget
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Nazanin Momeni Roudsari, Naser‐Aldin Lashgari, Saeideh Momtaz, Shaghayegh Abaft, Fatemeh Jamali, Pardis Safaiepour, Kiyana Narimisa, Gloria Jackson, Anusha Bishayee, Nima Rezaei et al. · 2021 · Pharmaceutics
Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Andrew M. Evens, Laurie Helen Sehn, Pedro Farinha, Beverly P. Nelson, Adekunle A. Raji, Yi Lu, Adam Brakman, Vamsi Parimi, Jane N. Winter, Paul T. Schumacker et al. · 2010 · Journal of Clinical Oncology
PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells
Mari Kaarbø, Øyvind Mikkelsen, Lene Malerød, Su Qu, Viola Hélène Lobert, Gulcan Akgul, Thomas Halvorsen, Gunhild Mari Mælandsmo, Fahri Saatcioglu · 2010 · Analytical Cellular Pathology
Angiogenin-mediated rRNA transcription in cancer and neurodegeneration.
Shuping Li, Guo‐fu Hu · 2010 · PubMed Central
Glutamine synthetase limits β-catenin–mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1
Dai, Weiwei, Shen, Jianliang, Yan, Junrong, Bott, Alex J., Maimouni, Sara, Daguplo, Heineken Q., Wang, Yujue, Khayati, Khoosheh, Guo, Jessie Yanxiang, Zhang, Lanjing et al. · 2022 · Journal of Clinical Investigation
Imaging of tumor glucose utilization with positron emission tomography
Andrea Bürkle, Wolfgang Weber · 2008 · Cancer and Metastasis Reviews
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer
Yota Yasumizu, Akira Miyajima, Takeo Kosaka, Yasumasa J. Miyazaki, Eiji Kikuchi, Mototsugu Oya · 2013 · The Journal of Urology
PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination
Johannes G. Czernin, Matthias Benz, Martin Allen-Auerbach · 2010 · European Journal of Radiology
HIF and fumarate hydratase in renal cancer
Sunil Sudarshan, William Marston Linehan, Len Neckers · 2007 · British Journal of Cancer
Immunohistochemical Detection of Changes in Tumor Hypoxia
James Russell, Sean Carlin, Sean A. Burke, Bixiu Wen, Kwangmo Yang, C. Clifton Ling · 2009 · International Journal of Radiation Oncology*Biology*Physics
Systems biology of robustness and homeostatic mechanisms
H. Frederik Nijhout, Janet A. Best, Michael C. Reed · 2018 · WIREs Systems Biology and Medicine
Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
Athanasia Pavlidou, Nikolaos Vlahos · 2014 · The Scientific World JOURNAL
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinhäuser, Federico Roncaroli, Rickmer Braren, Natalia Simona Pellegata · 2015 · Clinical Cancer Research
NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
Y Yang, Takayuki Ikezoe, Chie Nishioka, Kentaro Bandobashi, Tamotsu Takeuchi, Y Adachi, Makoto Kobayashi, Seisho Takeuchi, Harold Phillip Koeffler, Hirokuni Taguchi · 2006 · British Journal of Cancer
Biology of breast cancer during pregnancy using genomic profiling
Hamdy A. Azim, Sylvain Brohée, Fedro Alessandro Peccatori, Christine Desmedt, Sherene Loi, Diether Lambrechts, Patrizia Dell’Orto, Samira Majjaj, Vinu José, Nicole Rotmensz et al. · 2014 · Endocrine Related Cancer
Advances in the interaction of glycolytic reprogramming with lactylation
Yue Li, Qian Cao, Yibao Hu, Bisha He, Ting Cao, Yun Tang, Xiang Ping Zhou, Xiao Peng Lan, Shuang Liu · 2024 · Biomedicine & Pharmacotherapy
HIF-1α and Cancer Therapy
Mei Yee Koh, Taly R. Spivak-Kroizman, Garth Powis · 2009 · Recent results in cancer research/Recent Results in Cancer Research
Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-β in human chondrocytes
Hamid Y. Qureshi, Rasheed Ahmad, Judith Sylvester, Muhammad Zafarullah · 2007 · Cellular Signalling
Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity
Òscar M. Tirado, Silvia Mateo‐Lozano, Vicente Notario · 2005 · Oncogene
TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression
Benaya Rozen‐Zvi, Tomoko Hayashida, Susan C. Hubchak, Christian Hanna, Leonidas C. Platanias, H. William Schnaper · 2013 · American Journal of Physiology-Renal Physiology
Preclincial testing of Sorafenib and RAD001 in the Nf flox/flox ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging
Jianqiang Wu, Eva Dombi, Edwin Jousma, Richard Scott Dunn, Diana M. Lindquist, Beverly M. Schnell, Mi‐Ok Kim, AeRang Kim, Brigitte C. Widemann, Timothy P. Cripe et al. · 2011 · Pediatric Blood & Cancer
Protein kinase B (PKB/Akt) is required for the completion of meiosis in mouse oocytes
Yumi Hoshino, Eimei Sato · 2008 · Developmental Biology
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Hallvard Holdaas, Paolo DE SIMONE, Andreas Oliver Zuckermann · 2016 · Journal of Transplantation
Genomics and proteomics: Emerging technologies in clinical cancer research
Christine H. Chung, Shawn Levy, Pierre Chaurand, David Paul Carbone · 2006 · Critical Reviews in Oncology/Hematology
PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma
Alan Loh Ho, Shyamprasad Deraje Vasudeva, Marick E Lae, Tsuyoshi Saito, Violetta Barbashina, Cristina R. Antonescu, Marc Ladanyi, Gary K. Schwartz · 2012 · Cancer Research
INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Scott A. Tomlins, Mark A. Rubin, Arul M. Chinnaiyan · 2006 · Annual Review of Pathology Mechanisms of Disease
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- <i>Myc</i> Lymphoma by Restoring Oncogene-Induced Senescence
Wall, Meaghan, Poortinga, Gretchen, Stanley, Kym L., Lindemann, Ralph K., Bots, Michael, Chan, Christopher J., Bywater, Megan J., Kinross, Kathryn M., Astle, Megan V., Waldeck, Kelly et al. · 2013 · Cancer Discovery
Fungal Melanin and the Mammalian Immune System
Sichen Liu, Sirida Youngchim, Daniel Zamith‐Miranda, Joshua Daniel Nosanchuk · 2021 · Journal of Fungi
A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
Hao Zhang, Dror Berel, Yanping Wang, Ping Li, Neil A. Bhowmick, Robert A. Figlin, Hyung Lae Kim · 2013 · PLoS ONE
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong, Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda Lynn Bitting, Patricia A. Kartcheske, Elizabeth Embree, Karla K. Morris, Carolyn Winters, Tracy A. Jaffe et al. · 2013 · Clinical Genitourinary Cancer
Protein turnover in cardiac cell growth and survival
Nadia Hedhli, Michel Pelat, C. Depre · 2005 · Cardiovascular Research
Application of a priori established gene sets to discover biologically important differential expression in microarray data
Andrea Bild, Phillip G. Febbo · 2005 · Proceedings of the National Academy of Sciences